Treatment of cancer by activation of an antitumor immune response is now a widely practiced and well-accepted approach to therapy. However, despite dramatic responses in some patients, the high proportion of unresponsive patients points to a considerable unmet medical need. Although antibody therapies have led the way, small molecule immuno-oncology agents are close behind. This perspective provides an overview of some of the many small molecule approaches being explored. It encompasses small molecule modulators of validated targets such as programed cell death 1 (PD-1) as well as novel approaches still to be proven clinically.

中文翻译：

---

小分子免疫肿瘤治疗剂

现在，通过激活抗肿瘤免疫应答来治疗癌症是一种广泛实践且广为接受的治疗方法。然而，尽管某些患者反应显着，但无反应患者的比例很高，这表明医疗需求仍未得到满足。尽管抗体疗法已走在前列，但小分子免疫肿瘤药紧随其后。该观点概述了正在探索的许多小分子方法中的一些。它包括已验证靶标的小分子调节剂，例如程序性细胞死亡1（PD-1）以及尚待临床验证的新方法。